ETX-19477 is a potent, selective inhibitor of poly (ADP-ribose) glycohydrolase (PARG), an enzyme that plays a role in the DNA ...
Using menopausal hormone therapy (MHT) was not associated with an increased risk of breast cancer in women with inherited ...
Fast Track designation granted by U.S. FDA for evaluation of ETX-19477 in patients with BRCA-mutated, platinum-resistant ...
SAN ANTONIO – Using menopausal hormone therapy (MHT) was not associated with an increased risk of breast cancer in women with inherited mutations in the BRCA1 or BRCA2 genes, according to the results ...
Duplaix shared the show’s public service announcement on Instagram, reflecting on the storyline. “As an actress on Beyond the ...
The world’s first early-detection blood test for pancreatic cancer is set to be launched in Australia, and is predicted to ...
University of Manchester researchers have shown that analysis of fluid flushed through a fallopian tube holds promise for ...
Cedars-Sinai Medical Center ended 2025 on a high note thanks to a $30 million donation to establish a new research center. The gift – courtesy of the ...
The FDA has granted traditional approval to Rubraca (rucaparib) for metastatic castration-resistant prostate cancer.
In this study, researchers aimed to determine whether younger BRCA1/2 carriers who undergo oophorectomy can receive menopausal hormone therapy without increasing their risk of breast cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback